AstraZeneca mulls €240bn mega-merger with Gilead Sciences

Pharma firm AstraZeneca is considering a merger with US peer Gilead Sciences to create a company with a market value of $240bn.

Free, fast, fair

Continue reading this article and get instant access to even more investment news by registering your details below:

We will use the details you have shared to manage your registration. You agree to the processing, storage, sharing and use of this information for the purpose of managing your registration as described in our Privacy Policy.

We will use the details you have shared to manage your newsletter subscription. You agree to the processing, storage, sharing and use of this information for the purpose of managing your subscription as described in our Privacy Policy.

We will use the information you have shared for carefully considered and specific purposes, where we believe we have a legitimate case to do so, for example to send you communications about similar products and services we offer. You can find out more about our legitimate interest activity in our privacy policy.

‘We’ includes MoneyWeek and other Dennis Group brands as detailed here

Reset your password

A link has been emailed to you - check your inbox.



Don't have an account? Click here to register

Recommended

Three winners of the long-term biotech boom
Share tips

Three winners of the long-term biotech boom

Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management te…
22 Mar 2021
Stockmarkets shrug off turbulence
Stockmarkets

Stockmarkets shrug off turbulence

Stockmarkets have hit their first bout of turbulence of the year, but most are clinging onto January’s gains.
4 Feb 2021
The FTSE 100 has clawed back above 7,000 – how much higher can it go?
UK stockmarkets

The FTSE 100 has clawed back above 7,000 – how much higher can it go?

The FTSE 100 index has risen to over 7,000 for the first time in over a year – it now sits just above where it was in 1999. But its era of neglect cou…
19 Apr 2021
Get decades of growth at a discount with this healthcare investment trust
Investment trusts

Get decades of growth at a discount with this healthcare investment trust

Healthcare is set for strong long-term expansion but looks cheap. That makes this investment trust worth buying, says Max King.
19 Apr 2021

Most Popular

Lab-grown meat: how “moo’s law” will drive innovation
Soft commodities

Lab-grown meat: how “moo’s law” will drive innovation

Jim Mellon and Anthony Chow, co-founders of Aim-listed Agronomics, explain why they believe that “cellular agriculture” will benefit from massive long…
16 Apr 2021
The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Lab-grown meat: the new agricultural revolution
Soft commodities

Lab-grown meat: the new agricultural revolution

Vegan alternatives are taking off, but the future of food technology lies in lab-grown meat – cultivating steaks and burgers from animal cells, says A…
16 Apr 2021